Oteracil

DB03209ApprovedInvestigationalSmall molecule

Oteracil is a chemotherapy agent used in combination with tegafur, cisplatin and gimeracil to treat advanced gastric cancer. Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy.

Mechanism: Oteracil's main role within Teysuno is to reduce the activity of 5-FU within normal gastrointestinal mucosa, and therefore reduce's gastrointestinal toxicity. It functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU.
Curator reviewed · 1 reference
Primary indication: Oteracil is used as an adjunct to antineoplastic therapy.Curator reviewed · 1 structured indication
Formula / weight: C₄H₃N₃O₄ · 157.0843 g/mol (avg)
First approval: European Union, 2016
Also known as: 5-azaorotic acid · Allantoxanic acid · Oxonate · Oxonic Acid
Brand names: Teysuno

Resolves to

Compound

UNII5VT6420TIGCAS937-13-3ChEMBLCHEMBL181932ChEBI30863PubChem4604KEGGD06399

Structure

InChIKeyRYYCJUAHISIHTL-UHFFFAOYSA-NSMILESOC(=O)C1=NC(=O)NC(=O)N1

Targets

P11172UMPS

Transporters

O00182LGALS9

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

1Drug interactionStructured to mechanism, not free text

119Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

9ContraindicationsEach with its own population and attribute set

22Marketed productsAcross 6 countries and 7 labellers

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Oteracil, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In